JPMorgan Starts C4 Therapeutics (CCCC) at Overweight

October 9, 2026 3:22 AM

JPMorgan analyst Anupam Rama initiates coverage on C4 Therapeutics (NASDAQ: CCCC) with a Overweight rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found